X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (152) 152
clinical neurology (122) 122
index medicus (115) 115
male (107) 107
female (103) 103
parkinson's disease (95) 95
aged (88) 88
middle aged (80) 80
article (62) 62
dementia (53) 53
neurosciences (44) 44
neurology (42) 42
parkinson disease - complications (39) 39
neuropsychological tests (34) 34
parkinson disease - diagnosis (32) 32
parkinsons disease (31) 31
adult (28) 28
parkinson’s disease (28) 28
aged, 80 and over (27) 27
alzheimer's disease (27) 27
diagnosis (27) 27
alzheimers-disease (26) 26
cognition (26) 26
abridged index medicus (23) 23
biomarkers (23) 23
parkinson disease - physiopathology (23) 23
cognition disorders - etiology (22) 22
parkinson disease - drug therapy (22) 22
severity of illness index (21) 21
movement disorders (20) 20
neurodegenerative diseases (20) 20
pathology (20) 20
risk factors (20) 20
cohort studies (19) 19
depression (19) 19
parkinson disease - psychology (19) 19
parkinson disease - genetics (18) 18
alpha-synuclein (17) 17
further section (17) 17
impairment (17) 17
medical research (17) 17
cognitive impairment (16) 16
cognitive ability (15) 15
disease progression (15) 15
parkinson disease - epidemiology (15) 15
reproducibility of results (15) 15
analysis (14) 14
cognition disorders - diagnosis (14) 14
dopamine (14) 14
medicine, experimental (14) 14
parkinson disease (14) 14
prevalence (14) 14
risk (14) 14
brain (13) 13
mental disorders (13) 13
sleep behavior disorder (13) 13
surveys and questionnaires (13) 13
cross-sectional studies (12) 12
double-blind method (12) 12
genotype (12) 12
lewy bodies (12) 12
association (11) 11
case-control studies (11) 11
parkinson disease - diagnostic imaging (11) 11
parkinson disease - therapy (11) 11
psychiatry (11) 11
sensitivity and specificity (11) 11
treatment outcome (11) 11
alzheimers disease (10) 10
clinical trials (10) 10
dopamine transporter (10) 10
neuroimaging (10) 10
patients (10) 10
psychiatric status rating scales (10) 10
quality of life (10) 10
research (10) 10
tau (10) 10
analysis of variance (9) 9
disease (9) 9
dysfunction (9) 9
genetics (9) 9
levodopa (9) 9
magnetic resonance imaging (9) 9
medical colleges (9) 9
mutation (9) 9
neuropsychology (9) 9
olfaction (9) 9
parkinsons-disease (9) 9
proteins (9) 9
quality-of-life (9) 9
activities of daily living (8) 8
cognition & reasoning (8) 8
disruptive, impulse control, and conduct disorders - etiology (8) 8
epidemiology (8) 8
executive function (8) 8
memory (8) 8
mental status schedule (8) 8
mild cognitive impairment (8) 8
neurodegeneration (8) 8
rating-scale (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neurology, ISSN 0028-3878, 01/2013, Volume 80, Issue 2, pp. 176 - 180
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2017, Volume 12, Issue 5, p. e0175674
Objectives To assess the neurobiological substrate of initial cognitive decline in Parkinson's disease (PD) to inform patient management, clinical trial... 
INITIATIVE PPMI | DEMENTIA | ALZHEIMERS-DISEASE | MULTIDISCIPLINARY SCIENCES | INCIDENT | DISORDER | POLYMORPHISM | DIAGNOSTIC-CRITERIA | PLANNING ABILITY | LEWY BODIES | DECLINE | Brain-Derived Neurotrophic Factor - genetics | Dopamine Plasma Membrane Transport Proteins - metabolism | Parkinson Disease - complications | Humans | Middle Aged | Tomography, Emission-Computed, Single-Photon | Male | tau Proteins - cerebrospinal fluid | Cognitive Dysfunction - cerebrospinal fluid | Catechol O-Methyltransferase - genetics | Diffusion Tensor Imaging | Magnetic Resonance Imaging | Cognitive Dysfunction - epidemiology | Aged, 80 and over | Amyloid beta-Peptides - cerebrospinal fluid | Adult | Cognitive Dysfunction - genetics | Female | Aged | Polymorphism, Single Nucleotide | Biomarkers - cerebrospinal fluid | Cognitive Dysfunction - diagnostic imaging | Complications and side effects | Care and treatment | Parkinson's disease | Development and progression | Cognition disorders | Biological markers | Identification and classification | Brain | Cognitive ability | Nervous system | Cerebrospinal fluid | Risk factors | Eye | Design | Computed tomography | Education | Aging | Alzheimer's disease | Public health | Movement disorders | Deoxyribonucleic acid--DNA | Apolipoprotein E4 | Emotional behavior | Temporal lobe | Neurodegenerative diseases | Catechol | Cortex (visual) | Single photon emission computed tomography | Substrates | Neurology | Pathology | Thinning | Experimental design | Biomarkers | β-Amyloid | Dementia | Neuroimaging | Haplotypes | Mental disorders | Laboratories | Parkinsons disease | Visual perception | Atrophy | Dementia disorders | Dopamine | Review boards | Health risks | Pharmacology | Dentistry | Medicine | Brain research | Sleep | Brain-derived neurotrophic factor | Magnetic resonance imaging | Parietal lobe | Alzheimers disease | Psychiatry | Polymorphism | Deoxyribonucleic acid | DNA
Journal Article
Journal Article
The Journal of Nuclear Medicine, ISSN 0161-5505, 02/2005, Volume 46, Issue 2, pp. 227 - 232
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2017, Volume 12, Issue 5, p. e0177924
Parkinson disease patients develop clinically significant cognitive impairment at variable times over their disease course, which is often preceded by milder... 
APOLIPOPROTEIN-E EPSILON-4 | POSITRON-EMISSION-TOMOGRAPHY | ALZHEIMERS-DISEASE | MULTIDISCIPLINARY SCIENCES | VOLUME EFFECT CORRECTION | IN-VIVO | A-BETA | ALPHA-SYNUCLEIN | DIAGNOSTIC-CRITERIA | FLORBETAPIR F 18 | PET | Parkinson Disease - pathology | Dementia - pathology | Humans | Middle Aged | Cognition Disorders - pathology | Cognition Disorders - metabolism | Male | Positron-Emission Tomography - methods | Alzheimer Disease - pathology | Brain - metabolism | Dementia - metabolism | Amyloid - metabolism | Alzheimer Disease - metabolism | Amyloid beta-Peptides - metabolism | Brain - pathology | Cognition - physiology | Female | Plaque, Amyloid - metabolism | Aged | Parkinson Disease - metabolism | Ethylene Glycols - administration & dosage | Aniline Compounds - administration & dosage | Amyloidogenesis | Brain | Parkinson's disease | Gait | Memory | Cognitive ability | Disorders | Nervous system | Cognition | Rigidity | Epidemiology | Freezing | Proteins | Autopsy | Education | Tomography | Aging | Alzheimer's disease | Movement disorders | Quantitative analysis | Binding | Apolipoprotein E4 | Neurodegenerative diseases | Cortex | Regression analysis | Assessments | Apolipoproteins | Emissions | Studies | Pathology | Neurology | Radiology | β-Amyloid | Cognitive tasks | Dementia | Neuroimaging | Nuclear medicine | Neurosciences | Mental disorders | Laboratories | Physicians | Parkinsons disease | Risk | Population studies | Accumulation | Apolipoprotein E | Dementia disorders | Qualitative analysis | Deposition | Autopsies | Medical imaging | Health risks | Medicine | Brain research | Cognition & reasoning | Magnetic resonance imaging | Gene frequency | Alleles | Amyloidosis | In vivo methods and tests | Reliability | Positron emission tomography | Psychiatry
Journal Article